QQQ   431.44 (+0.09%)
AAPL   169.80 (-1.67%)
MSFT   415.82 (+0.53%)
META   501.22 (+0.20%)
GOOGL   154.69 (-0.11%)
AMZN   183.82 (+0.11%)
TSLA   157.28 (-2.60%)
NVDA   876.78 (+1.95%)
AMD   163.97 (+2.28%)
NIO   3.82 (-1.80%)
BABA   69.61 (-1.43%)
T   16.10 (-0.86%)
F   12.09 (-1.14%)
MU   121.86 (+0.40%)
GE   156.71 (+1.96%)
CGC   6.71 (-3.87%)
DIS   114.04 (+0.97%)
AMC   2.73 (+10.53%)
PFE   25.71 (-0.77%)
PYPL   63.54 (+0.05%)
XOM   118.70 (-0.82%)
QQQ   431.44 (+0.09%)
AAPL   169.80 (-1.67%)
MSFT   415.82 (+0.53%)
META   501.22 (+0.20%)
GOOGL   154.69 (-0.11%)
AMZN   183.82 (+0.11%)
TSLA   157.28 (-2.60%)
NVDA   876.78 (+1.95%)
AMD   163.97 (+2.28%)
NIO   3.82 (-1.80%)
BABA   69.61 (-1.43%)
T   16.10 (-0.86%)
F   12.09 (-1.14%)
MU   121.86 (+0.40%)
GE   156.71 (+1.96%)
CGC   6.71 (-3.87%)
DIS   114.04 (+0.97%)
AMC   2.73 (+10.53%)
PFE   25.71 (-0.77%)
PYPL   63.54 (+0.05%)
XOM   118.70 (-0.82%)
QQQ   431.44 (+0.09%)
AAPL   169.80 (-1.67%)
MSFT   415.82 (+0.53%)
META   501.22 (+0.20%)
GOOGL   154.69 (-0.11%)
AMZN   183.82 (+0.11%)
TSLA   157.28 (-2.60%)
NVDA   876.78 (+1.95%)
AMD   163.97 (+2.28%)
NIO   3.82 (-1.80%)
BABA   69.61 (-1.43%)
T   16.10 (-0.86%)
F   12.09 (-1.14%)
MU   121.86 (+0.40%)
GE   156.71 (+1.96%)
CGC   6.71 (-3.87%)
DIS   114.04 (+0.97%)
AMC   2.73 (+10.53%)
PFE   25.71 (-0.77%)
PYPL   63.54 (+0.05%)
XOM   118.70 (-0.82%)
QQQ   431.44 (+0.09%)
AAPL   169.80 (-1.67%)
MSFT   415.82 (+0.53%)
META   501.22 (+0.20%)
GOOGL   154.69 (-0.11%)
AMZN   183.82 (+0.11%)
TSLA   157.28 (-2.60%)
NVDA   876.78 (+1.95%)
AMD   163.97 (+2.28%)
NIO   3.82 (-1.80%)
BABA   69.61 (-1.43%)
T   16.10 (-0.86%)
F   12.09 (-1.14%)
MU   121.86 (+0.40%)
GE   156.71 (+1.96%)
CGC   6.71 (-3.87%)
DIS   114.04 (+0.97%)
AMC   2.73 (+10.53%)
PFE   25.71 (-0.77%)
PYPL   63.54 (+0.05%)
XOM   118.70 (-0.82%)

Viridian Therapeutics (VRDN) Stock Price, News & Analysis

$15.10
-0.54 (-3.45%)
(As of 03:58 PM ET)
Today's Range
$15.03
$15.54
50-Day Range
$15.64
$20.17
52-Week Range
$10.93
$30.30
Volume
521,153 shs
Average Volume
935,818 shs
Market Capitalization
$947.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.60

Viridian Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
143.2% Upside
$36.60 Price Target
Short Interest
Bearish
15.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.76mentions of Viridian Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$10 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($4.39) to ($4.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.81 out of 5 stars

Medical Sector

643rd out of 930 stocks

Medical Laboratories Industry

14th out of 19 stocks

VRDN stock logo

About Viridian Therapeutics Stock (NASDAQ:VRDN)

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

VRDN Stock Price History

VRDN Stock News Headlines

Viridian Therapeutics (NASDAQ: VRDN)
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Unveiling 4 Analyst Insights On Viridian Therapeutics
VRDN Sep 2024 20.000 put
VRDN Apr 2024 20.000 put
Viridian Therapeutics GAAP EPS of -$1.35
VRDN Mar 2024 30.000 put
See More Headlines
Receive VRDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/16/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:VRDN
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.60
High Stock Price Target
$46.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+143.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-237,730,000.00
Net Margins
-75,711.48%
Pretax Margin
-75,711.46%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
$4.48 per share

Miscellaneous

Free Float
61,870,000
Market Cap
$944.69 million
Optionable
Optionable
Beta
1.07
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Stephen F. Mahoney J.D. (Age 52)
    MBA, CEO, President & Director
  • Dr. Eric N. Olson Ph.D.
    Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael R. Bristow M.D. (Age 79)
    Ph.D., Co-Founder & Member of the Scientific Advisory Board
  • Dr. Marvin H. Caruthers Ph.D. (Age 84)
    Co-Founder & Scientific Advisory Board Member
  • Mr. Vahe Bedian Ph.D.
    Co-Founder & Scientific Advisor
  • Mr. Seth Harmon
    Senior VP of Finance and Accounting, Principal Financial & Accounting Officer
  • Mr. Thomas W. Beetham J.D. (Age 54)
    MBA, Chief Operating Officer
  • Ms. Jennifer Tousignant J.D.
    Chief Legal Officer
  • Mr. John A. Jordan
    Vice President of Investor Relations & Corporate Communications
  • Mr. Anthony Casicano (Age 47)
    Chief Commercial Officer

VRDN Stock Analysis - Frequently Asked Questions

Should I buy or sell Viridian Therapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRDN shares.
View VRDN analyst ratings
or view top-rated stocks.

What is Viridian Therapeutics' stock price target for 2024?

10 brokers have issued 12-month price targets for Viridian Therapeutics' shares. Their VRDN share price targets range from $25.00 to $46.00. On average, they anticipate the company's share price to reach $36.60 in the next twelve months. This suggests a possible upside of 143.2% from the stock's current price.
View analysts price targets for VRDN
or view top-rated stocks among Wall Street analysts.

How have VRDN shares performed in 2024?

Viridian Therapeutics' stock was trading at $21.78 at the start of the year. Since then, VRDN stock has decreased by 30.9% and is now trading at $15.05.
View the best growth stocks for 2024 here
.

Are investors shorting Viridian Therapeutics?

Viridian Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,470,000 shares, an increase of 24.3% from the March 15th total of 7,620,000 shares. Based on an average daily trading volume, of 962,900 shares, the days-to-cover ratio is currently 9.8 days.
View Viridian Therapeutics' Short Interest
.

When is Viridian Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VRDN earnings forecast
.

How were Viridian Therapeutics' earnings last quarter?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) released its quarterly earnings data on Tuesday, February, 27th. The company reported ($1.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by $0.37. The firm earned $0.07 million during the quarter, compared to analysts' expectations of $0.15 million. Viridian Therapeutics had a negative trailing twelve-month return on equity of 121.80% and a negative net margin of 75,711.48%. The firm's revenue for the quarter was down 31.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.13) EPS.

How do I buy shares of Viridian Therapeutics?

Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VRDN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners